Supplements

DHEA: a hormone precursor, oral versus vaginal prasterone, aging claims, different guideline contexts, fertility evidence, and safety

7 sources · Latest source check 2026-10-20 UTC

On this page

DHEA means dehydroepiandrosterone, an endogenous steroid precursor converted to androgens and estrogens. The pharmaceutical name prasterone also refers to this substance. An oral supplement and a prescription vaginal insert have different exposures and evidence. Ingredient identity alone does not transfer an indication from one route to another.[1]

What the label or study actually concerns

What the label or study actually concerns
Term	Meaning
DHEA-S	The sulfated form measured in selected studies.[4]
Dyspareunia	Painful intercourse, the symptom specified in the vaginal medicine indication.[1]
Primary adrenal insufficiency	A diagnosed adrenal disorder; distinct from general wellness hormone marketing.[3]
IVF poor response	A particular fertility-treatment population, rather than all people trying to conceive.[6]

The 2014 guideline recommended against routine use

The Endocrine Society’s androgen guideline recommended against routine DHEA use in normal women or those with adrenal insufficiency because effectiveness and safety data were limited. It also cautioned against diagnosing an androgen-deficiency syndrome in healthy women without a well-defined syndrome linking levels and symptoms. Its 2014 publication date is retained.[2]

A low measurement does not define a universal treatment target

A laboratory value, a symptom syndrome and a demonstrated treatment benefit are different forms of evidence. The guidance is not a current blanket appraisal of every route or later indication. Complete guideline updates and indication-specific evidence need review before its recommendation is generalized to all DHEA-related care.[2]

A historical two-year experiment is not a lifespan study

The 2006 study enrolled 87 older men and 57 older women selected for low hormone measurements. It compared DHEA, testosterone where applicable and placebo over two years. The original report describes increases in DHEA-S with DHEA treatment. A changed concentration is not, by itself, a clinical benefit or a measure of biological rejuvenation.[4]

Aging claims require more than hormone restoration

The design cannot be treated as evidence that every older adult needs supplementation or that a retail product extends life. Complete endpoint, clinically important effect and later-study reconciliation remain pending here. This page does not substitute a hormone-based aging score for function, wellbeing, disease events or survival.[4]

The older menopause synthesis did not find a quality-of-life benefit

Cochrane’s 2015 review included 28 trials with 1,273 participants and searched through June 2014. It found no clear quality-of-life improvement, uncertain menopausal-symptom effects and a small sexual-function benefit. Androgenic adverse effects, particularly acne, were more frequent. These results should retain both efficacy and harm information.[5]

A pooled route comparison is not proof of interchangeability

Most included trials used oral DHEA. The review’s comparison of oral and vaginal study subgroups did not establish that the routes are equivalent. The symptom, preparation, study population and evidence age matter. Its historical synthesis also predates the vaginal product’s initial US approval in 2016.[5]

The 2024 fertility review separated DHEA from testosterone

The updated review found that DHEA pretreatment likely made little to no difference to live birth/ongoing pregnancy and clinical pregnancy in IVF poor responders. Testosterone pretreatment had a different pooled result. These hormones cannot be merged into a single claim that androgen supplements improve fertility.[6]

Egg-related measurements and live birth are different endpoints

The review’s outcome certainty belongs to its authors, not to an independent Atlas grading exercise. Its participants and assisted-reproduction setting limit generalization to spontaneous conception or everyone with a low hormone value. Harms, multiple pregnancy, preparation and treatment-duration questions remain relevant.[6]

The vaginal indication is specific

The January 2026 INTRAROSA label specifies moderate-to-severe menopausal dyspareunia associated with vulvar and vaginal atrophy. It lists undiagnosed abnormal genital bleeding as a contraindication and a separate breast-cancer warning, noting that the product was not studied in people with that history. The label’s categories should be represented accurately.[1]

A plant starting material is different from a finished hormone

Wild yam contains diosgenin, a plant compound that can be converted into steroid compounds in a laboratory. That manufacturing possibility is not evidence that the unconverted root or cream supplies a measured amount of DHEA. Memorial Sloan Kettering specifically notes the lack of evidence for human conversion of diosgenin into progesterone. Read the actual ingredients rather than treating wild-yam wording as the name of a hormone medicine.[7]

Evidence & uncertainty

Routine DHEA use has limited support. A hormone measurement does not demonstrate rejuvenation, and guidance depends on the clinical context.[2][4]

Selected-source overview · Independent review pending

Published questions

Does ingredient identity make oral DHEA equivalent to vaginal prasterone?

Selected-source overview · Independent review pending. Read the evidence context.

Routes and evidence differ.[1]

Evidence behind this answer

INTRAROSA prasterone vaginal inserts: prescribing information
prescribing information · 2026
Selected original full-label mechanism, indication, contraindication and warning passages inspected; complete route-specific clinical appraisal pending · January 2026 label: endogenous precursor, route/indication, bleeding contraindication and separate breast-cancer warning